Antitumor Activity of Rapamycin in a Transgenic Mouse Model of ErbB2-Dependent Human Breast Cancer
Open Access
- 15 June 2005
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 65 (12) , 5325-5336
- https://doi.org/10.1158/0008-5472.can-04-4589
Abstract
Immunophenotypes in lymphoproliferative diseases (LPD) are prognostically significant, yet causative factors for these conditions, and specifically those associated with heritable risk, remain elusive. The full spectrum of LPD seen in humans occurs in dogs, but the incidence and lifetime risk of naturally occurring LPD differs among dog breeds. Taking advantage of the limited genetic heterogeneity that exists within dog breeds, we tested the hypothesis that the prevalence of LPD immunophenotypes would differ among different breeds. The sample population included 1,263 dogs representing 87 breeds. Immunophenotype was determined by the presence of clonal rearrangements of immunoglobulin heavy chain or T-cell receptor γ chain. The probability of observing the number of B-cell or T-cell tumors in a particular breed or breed group was compared with three reference populations. Significance was computed using χ2 test, and logistic regression was used to confirm binomial predictions. The data show that, among 87 breeds tested, 15 showed significant differences from the prevalence of LPD immunophenotypes seen across the dog population as a whole. More significantly, elevated risk for T-cell LPD seems to have arisen ancestrally and is retained in related breed groups, whereas increased risk for B-cell disease may stem from different risk factors, or combinations of risk factors, arising during the process of breed derivation and selection. The data show that domestic dogs provide a unique and valuable resource to define factors that mediate risk as well as genes involved in the initiation of B-cell and T-cell LPD.Keywords
This publication has 44 references indexed in Scilit:
- Activation of the Akt/Mammalian Target of Rapamycin/4E-BP1 Pathway by ErbB2 Overexpression Predicts Tumor Progression in Breast CancersClinical Cancer Research, 2004
- Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitiveNature Cell Biology, 2004
- A vision for the National Cancer Program in the United StatesNature Reviews Cancer, 2004
- Drug-Eluting StentsAnnual Review of Medicine, 2004
- Angiogenic Acceleration of Neu Induced Mammary Tumor Progression and MetastasisCancer Research, 2004
- Targeting HIF-1 for cancer therapyNature Reviews Cancer, 2003
- Endothelial-pericyte interactions in angiogenesisCell and tissue research, 2003
- The biology of VEGF and its receptorsNature Medicine, 2003
- The Role of the Epidermal Growth Factor Receptor Family in Mammary Tumorigenesis and MetastasisExperimental Cell Research, 1999
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987